|
Showing 1 - 6 of
6 matches in All Departments
Neuroinflammation is a burgeoning area of interest in academia and
biopharma, with a broadly acknowledged role in many central nervous
system (CNS) disorders. However, there is little agreement on the
pathophysiological mechanisms that underlie the manifestations of
neuroinflammation in the CNS compartment and how neuroinflammation
operates as a driver and also as a consequence of disease in the
brain. Moreover, another unclear area is how to translate increased
understanding of the mechanisms that underlie neuroinflammation and
its manifestations in the CNS to therapeutics. To address these
gaps in understanding mechanisms and how to translate that
understanding into therapeutics, the Forum on Neuroscience and
Nervous System Disorders of the National Academies of Sciences,
Engineering, and Medicine convened a workshop on March 20-21, 2017,
bringing together key leaders in the field from industry, academia,
and governmental agencies to explore the role and mechanisms of
neuroinflammation in a variety of CNS diseases. The workshop also
considered strategies to advance the identification and validation
of biomarkers of neuroinflammation that could accelerate
development of therapies, bringing much-needed treatments to
patients with disorders ranging from neuroinflammatory diseases
such as multiple sclerosis (MS) to neuropsychiatric disorders such
as depression. This publication summarizes the presentations and
discussions from the workshop. Table of Contents Front Matter 1
Introduction and Overview 2 Biomarkers of Neuroinflammation:
Challenges and Potential Opportunities 3 State of the Science of
Neuroinflammation in Central Nervous System Disorders 4
Neuroinflammation in Disease 5 Neuroimaging Biomarkers: Current
Initiatives and Opportunities 6 Cerebrospinal Fluid and Other Fluid
Biomarkers: Current Initiatives and Opportunities 7 Potential
Mechanisms for Moving Forward Appendix A References Appendix B
Workshop Agenda Appendix C Registered Attendees
|
Neuroforensics - Exploring the Legal Implications of Emerging Neurotechnologies: Proceedings of a Workshop (Paperback)
National Academies of Sciences, Engineering, and Medicine, Policy and Global Affairs, Committee on Science, Technology, and Law, Health and Medicine Division, Board on Health Sciences Policy, …
|
R1,183
Discovery Miles 11 830
|
Ships in 12 - 17 working days
|
Technological advances in noninvasive neuroimaging,
neurophysiology, genome sequencing, and other methods together with
rapid progress in computational and statistical methods and data
storage have facilitated large-scale collection of human genomic,
cognitive, behavioral, and brain-based data. The rapid development
of neurotechnologies and associated databases has been mirrored by
an increase in attempts to introduce neuroscience and behavioral
genetic evidence into legal proceedings. In March 2018, the
National Academies of Science, Engineering and Medicine organized a
workshop in order to explore the current uses of neuroscience and
bring stakeholders from neuroscience and legal societies together
in both the United Kingdom and the United States. Participants
worked together to advance an understanding of neurotechnologies
that could impact the legal system and the state of readiness to
consider these technologies and where appropriate, to integrate
them into the legal system. This publication summarizes the
presentations and discussions from the workshop. Table of Contents
Front Matter 1 Introduction and Background 2 Use of
Neurotechnologies and Neuroscience in Legal Settings: Case Studies
3 Looking into the Future: Novel Uses of Emerging Neurotechnologies
with Potential Legal Applications 4 Developing a Framework for Use
of Evidence from Emerging Neurotechnologies 5 Moving Forward:
Potential Next Steps Appendix A References Appendix B Workshop
Agenda Appendix C Registered Attendees
Chronic pain is one of the most prevalent, costly, and disabling
health conditions in the United States. Estimates show that more
than 11 percent of the American population suffer from chronic
pain, yet the federal pain research investment has been minimal. In
parallel with a gradual increased recognition of the problems of
treating chronic pain, the opioid epidemic has emerged as a growing
public health emergency. The intersection of these two crises lies
in the fact that an unintended consequence of treating pain has
been an increasing number of opioid prescriptions and diversion of
drugs for illicit purposes. In May 2017, the National Institutes of
Health (NIH), and the National Institute on Drug Abuse announced a
public?private partnership to develop solutions to the opioid
crisis and cut in half the time it takes to develop non-addictive
analgesics. To advance the planning of NIH's anticipated
public?private partnerships, the National Academies' Forum on
Neuroscience and Nervous Systems Disorders hosted a public workshop
that brought together a diverse group of stakeholders from
academia, federal agencies, advocacy organizations and companies
developing therapeutics for pain and opioid use disorders.
Participants discussed potential strategies to accelerate
development of non-addictive pain medications and treatments for
opioid use disorders. This publication summarizes the presentations
and discussions from the workshop. Table of Contents Front Matter 1
Introduction and Background 2 Exploring Challenges to Developing
Treatments for Pain and Opioid Use Disorders 3 Exploring the State
of the Science and Preclinical Models for Pain Therapeutic
Development 4 Clinical Development of Non-Addictive Pain
Medications 5 Therapeutic Development for Opioid Use Disorders and
Overdose Prevention and Reversal 6 PublicPrivate Partnerships to
Advance Pain and Opioid Use Disorders Research and Development
Appendix A References Appendix B Workshop Agenda Appendix C
Registered Attendees
From its very beginning, neuroscience has been fundamentally
interdisciplinary. As a result of rapid technological advances and
the advent of large collaborative projects, however, neuroscience
is expanding well beyond traditional subdisciplines and
intellectual boundaries to rely on expertise from many other
fields, such as engineering, computer science, and applied
mathematics. This raises important questions about to how to
develop and train the next generation of neuroscientists to ensure
innovation in research and technology in the neurosciences. In
addition, the advent of new types of data and the growing
importance of large datasets raise additional questions about how
to train students in approaches to data analysis and sharing. These
concerns dovetail with the need to teach improved scientific
practices ranging from experimental design (e.g., powering of
studies and appropriate blinding) to improved sophistication in
statistics. Of equal importance is the increasing need not only for
basic researchers and teams that will develop the next generation
of tools, but also for investigators who are able to bridge the
translational gap between basic and clinical neuroscience.
Developing a 21st Century Neuroscience Workforce is the summary of
a workshop convened by the Institute of Medicine's Forum on
Neuroscience and Nervous System Disorders on October 28 and
29,2014, in Washington, DC, to explore future workforce needs and
how these needs should inform training programs. Workshop
participants considered what new subdisciplines and collaborations
might be needed, including an examination of opportunities for
cross-training of neuroscience research programs with other areas.
In addition, current and new components of training programs were
discussed to identify methods for enhancing data handling and
analysis capabilities, increasing scientific accuracy, and
improving research practices. This report highlights the
presentation and discussion of the workshop. Table of Contents
Front Matter 1 Introduction and Overview 2 Training Neuroscientists
in Basic Research, Tool and Technology Development, and Big Data 3
Improving Training in Protocol Design, Experimental Rigor, and
Quantitative Skills 4 Training in Transdisciplinary Research 5
Enhancing Training to Support Translational Research Appendix A:
References Appendix B: Workshop Agenda Appendix C: Registered
Attendees Appendix D: Participant Biographies
Improving and Accelerating Therapeutic Development for Nervous
System Disorders is the summary of a workshop convened by the IOM
Forum on Neuroscience and Nervous System Disorders to examine
opportunities to accelerate early phases of drug development for
nervous system drug discovery. Workshop participants discussed
challenges in neuroscience research for enabling faster entry of
potential treatments into first-in-human trials, explored how new
and emerging tools and technologies may improve the efficiency of
research, and considered mechanisms to facilitate a more effective
and efficient development pipeline. There are several challenges to
the current drug development pipeline for nervous system disorders.
The fundamental etiology and pathophysiology of many nervous system
disorders are unknown and the brain is inaccessible to study,
making it difficult to develop accurate models. Patient
heterogeneity is high, disease pathology can occur years to decades
before becoming clinically apparent, and diagnostic and treatment
biomarkers are lacking. In addition, the lack of validated targets,
limitations related to the predictive validity of animal models -
the extent to which the model predicts clinical efficacy - and
regulatory barriers can also impede translation and drug
development for nervous system disorders. Improving and
Accelerating Therapeutic Development for Nervous System Disorders
identifies avenues for moving directly from cellular models to
human trials, minimizing the need for animal models to test
efficacy, and discusses the potential benefits and risks of such an
approach. This report is a timely discussion of opportunities to
improve early drug development with a focus toward preclinical
trials.
The Institute of Medicine (IOM) Forum on Neuroscience and Nervous
System Disorders, in collaboration with the IOM Forum on Drug
Discovery, Development, and Translation, convened a workshop on
January 20-21, 2015, to explore policy changes that might increase
private sector investment in research and development innovation
that fills unmet medical needs for central nervous system (CNS)
disorders. Workshop participants strategized about how to
incentivize companies to fortify their CNS drug development
programs, shrinking obstacles that currently deter ventures.
Representatives from academia, government agencies, patient groups,
and industry gathered to share information and viewpoints, and to
brainstorm about budget-neutral policy changes that could help
widen the pipeline toward drugs that address unmet needs for CNS
disorders. This report summarizes the presentations and discussion
of the workshop. Table of Contents Front Matter 1 Introduction and
Overview 2 Improving Market Protection 3 Strengthening the
Regulatory Pathway 4 Patient Benefit and Engagement Appendix A:
References Appendix B: Workshop Agenda Appendix C: Registered
Attendees Appendix D: Participant Biographies
|
You may like...
Catan
(16)
R1,150
R889
Discovery Miles 8 890
|